Sandip Kapadia
2017 - Intercept Pharmaceuticals
In 2017, Sandip Kapadia earned a total compensation of $2.1M as Chief Financial Officer at Intercept Pharmaceuticals, a 49% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $188,594 |
|---|---|
| Option Awards | $749,231 |
| Salary | $425,000 |
| Stock Awards | $750,260 |
| Other | $23,930 |
| Total | $2,137,016 |
Kapadia received $750.3K in stock awards, accounting for 35% of the total pay in 2017.
Kapadia also received $188.6K in non-equity incentive plan, $749.2K in option awards, $425K in salary and $23.9K in other compensation.
Rankings
In 2017, Sandip Kapadia's compensation ranked 5,193rd out of 14,666 executives tracked by ExecPay. In other words, Kapadia earned more than 64.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,193 out of 14,666 | 65th |
Division Manufacturing | 1,849 out of 5,772 | 68th |
Major group Chemicals And Allied Products | 549 out of 2,075 | 74th |
Industry group Drugs | 424 out of 1,731 | 76th |
Industry Pharmaceutical Preparations | 333 out of 1,333 | 75th |
Source: SEC filing on April 27, 2018.
Kapadia's colleagues
We found four more compensation records of executives who worked with Sandip Kapadia at Intercept Pharmaceuticals in 2017.
News
Intercept Pharmaceuticals CEO Jerome Durso's 2021 pay jumps 101% to $7.9M
May 2, 2022
Harmony Biosciences Holdings CFO Sandip Kapadia's 2021 pay jumps 171% to $6.2M
April 8, 2022
Intercept Pharmaceuticals CEO Mark Pruzanski's 2020 pay slips 3% to $6.4M
April 27, 2021
Intercept Pharmaceuticals CEO Mark Pruzanski's 2019 pay jumps 46% to $6.6M
April 29, 2020
Intercept Pharmaceuticals CEO Mark Pruzanski's 2018 pay falls 26% to $4.5M
April 30, 2019